Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Dove soap maker Unilever signals pursuit of GSK consumer arm; shares fall

EconomyJan 17, 2022 10:55AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
2/2 © Reuters. FILE PHOTO: Unilever headquarters in Rotterdam, Netherlands August 21, 2018. REUTERS/Piroschka van de Wouw/File Photo 2/2

By Pushkala Aripaka, Keith Weir and Pamela Barbaglia

(Reuters) -Unilever signalled on Monday it would pursue a deal for GSK's consumer business, calling it a "strong strategic fit", but Unilever (NYSE:UL) shares slid more than 8%, highlighting investors' doubts about its 50-billion-pound ($68.4 billion) offer.

GlaxoSmithKline (NYSE:GSK) confirmed over the weekend that it had rejected nL1N2TV079 three bids from the Dove soap maker for the consumer healthcare business, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller.

GSK, led by Emma Walmsley, has hired Goldman Sachs (NYSE:GS) and Citigroup (NYSE:C) to review Unilever's approach but it will not engage in talks unless Unilever bumps up its offer, sources familiar with the matter said.

GSK's shares jumped 6% to their highest level since May 2020. It said on Saturday Unilever's proposal "fundamentally undervalued" the consumer business, adding that it would stick to its plan of listing the division this year.

"Initial feedback on the deal from investors over the weekend has been almost uniformly negative," Jefferies analysts said in a note. Others noted Unilever's share price fall indicated a lack of confidence in its management and concern over the price.

The Marmite spread maker, however, defended the bid for the GSK consumer business, in which U.S. drugs company Pfizer (NYSE:PFE) owns a 32% stake.

"The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets," Unilever said, pointing to synergies in the oral care and vitamin supplements business.

GSK and Pfizer would open negotiations with Unilever's boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds, a source familiar with Pfizer's strategy said.

The source called the business a "legitimate standalone candidate", adding its market value could rise to almost $100 billion once the business was spun out and listed.

"Right now there is more value in a spin-off but if Unilever is ready to go north of 60 billion pounds then a dialogue could start," he said.

GSK declined to comment and Pfizer did not immediately respond to a request for comment on the fate of GSK's consumer business.


GSK laid out plans nL4N2R82AU for a separate listing of the consumer arm in June last year, following pressure from investors to explore a shake-up of the company and focus on its pharmaceuticals business.

A Unilever buyout of the consumer division would be one of the largest ever on the London market, and one of the biggest deals globally since the start of the COVID-19 pandemic.

It would also boost Unilever's growth strategy, as management has been under pressure to turn around the company's languishing stock price and cope with high costs and slim margins, but raises questions nL4N2TX2WJ about its strategy.

Some analysts expressed doubts over Unilever's ability to sweeten its offer to GSK.

"Given vocal investor concern of late and Unilever's share price reaction this morning, this could prevent a higher offer from materialising," said Chris Beckett, head of equity research at Quilter Cheviot.

Reports of buying interest in GSK's consumer arm, including from private equity players, have been doing the rounds for a while.

"It's a little surprising that (GSK and Pfizer) haven't ripped Unilever's arm off at £50bn, as it's a decent price, with the only question being as to whether it's the right one," CMC Markets analyst Michael Hewson said in a note.

"It might be for GlaxoSmithKline and Pfizer, however there is a feeling that for Unilever it could well prove to be too high a price," Hewson added.

Unilever, which is set to announce an initiative later this month to strengthen its business, said on Monday it was committed to "strict financial discipline" for any acquisitions, adding that such deals would be accompanied by the divestment of lower margin businesses or brands.

($1 = 0.7312 pounds)

Dove soap maker Unilever signals pursuit of GSK consumer arm; shares fall

Related Articles

ABB targets faster growth for motion business
ABB targets faster growth for motion business By Reuters - May 17, 2022

ZURICH (Reuters) - ABB is aiming to increase sales at its motion business 50% quicker than the overall market for electric motors, the Swiss engineering company said on Tuesday...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Privacy Please
WTIHedge Jan 17, 2022 10:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They should have waited until its listed and floundered. No way its worth more than 60B
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email